Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis

Ranjan Suri, Lindsay J. Marshall, Colin Wallis, Christopher Metcalfe, Andrew Bush, Janis K. Shute

Research output: Contribution to journalArticle

Abstract

Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis (CF), but it may liberate cationic mediators bound to DNA in the airways. An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutrophilic inflammation. We compared the effect of rhDNase and HS on cationic proinflammatory mediators in CF sputum. In a randomized, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7% HS. Sputum levels of total interleukin-8 (IL-8), free IL-8, myeloperoxidase, eosinophil cationic protein, and neutrophil elastase (NE) activity were measured before and after each treatment. The change in mediator levels from baseline with daily rhDNase and HS was not significant; however, with alternate-day rhDNase, there was an increase in free IL-8. When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected. Only changes in NE activity were associated with changes in lung function. In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.
Original languageEnglish
Pages (from-to)352-355
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume166
Issue number3
DOIs
Publication statusPublished - 1 Aug 2002

Keywords

  • cystic fibrosis
  • saline
  • rhDNase
  • inflammation

Fingerprint Dive into the research topics of 'Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis'. Together they form a unique fingerprint.

  • Cite this